Analyzing the efficacy of a novel method for detecting achromatopsia
DOI: 10.32364/2311-7729-2024-24-2-1
N.V. Sukhanova1, S.I. Rychkova2,3,4, V.G. Likhvantseva5, R.I. Sandimirov3, V.V. Kadyshev1, R.A. Zinchenko1
1Research Center for Medical Genetics, Moscow, Russian Federation
2Institute for Information Transmission Problems of the RAS (Kharkevich Institute), Moscow, Russian Federation
3Pirogov Russian National Research Medical University, Moscow, Russian Federation
4A.I. Burnazyan Federal Medical Biophysical Center of the Federal Medical Biological Agency of Russia, Moscow, Russian Federation
5Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russian Federation, Moscow, Russian Federation
Aim: to assess the efficacy of a novel method for diagnosing achromatopsia.
Patients and Methods: twenty patients with congenital achromatopsia established by genetic testing were enrolled. Sixteen (80%) patients were diagnosed with mutations in the CNGB3 gene and 4 (20%) patients were diagnosed with mutations in the CNGA3 gene. The control group 1 (with eye diseases) included 37 patients with congenital optic atrophy and 5 patients with oculocutaneous albinism. The control group 2 (without eye diseases) included 40 individuals. At the initial stage of the study, we compared the perception of brightness of chromatic and achromatic images in patients with achromatopsia. To this end, we employed our own images with specific characteristics of color tone, lightness (brightness), and saturation. The results of the first phase have demonstrated that for most patients with achromatop-sia, the lightest and least distinguishable images on a white background are blue. In light of this, we developed tests to detect achromatopsia (tests #1 and #2). Each test comprises four gray silhouette images (with a lightness of 80% for test #1 and 50% for test #2) and four blue images (R0/G255/B255). For the blue images, saturation is maximal (S 100%) in both tests, while luminosity is L 80% for test #1 and L 50% for test #2.
Results: all individuals in the control group 2, patients with optic atrophy and oculocutaneous albinism, were able to see all blue and gray images of both tests and easily identified the blue images corresponding to the gray (achromatic) ones. In the first test, 95% of patients with achromatopsia (n=19) were unable to see blue images or distinguish their shape from gray images. In contrast, all patients were able to distinguish the shape of gray images of the same lightness and specify them. In test #2 (L 50%), the majority of patients (n=13, 65%) exhibited difficulties with the shape of blue images. The remaining seven patients (35%) demonstrated the ability to name blue images and match them to gray images. Two of them were diagnosed with mutations in the CNGA3 gene, while five of them were diagnosed with mutations in the CNGB3 gene. Therefore, the cone system disorder in these patients was less severe than in the others.
Conclusion: the achromatopsia test, developed on the basis of comparative analysis of perceived luminosity of chromatic and achromatic images, is simple and accessible. This test provides preliminary differential diagnosis with other eye diseases and determines the most appropriate strategy of further examinations to establish the diagnosis.
Keywords: achromatopsia, color vision, method to diagnose achromatopsia, color per-ception abnormality, monochromacy, color vision deficiency, color disfunction.
For citation: Sukhanova N.V., Rychkova S.I., Likhvantseva V.G., Sandimirov R.I., Kadyshev V.V., Zinchenko R.A. Analyzing the efficacy of a novel method for detecting achromatopsia. Russian Journal of Clinical Ophthalmology. 2024;24(2):49–54 (in Russ.). DOI: 10.32364/2311-7729-2024-24-2-1.
Acknowledgments
The authors are grateful to the Patient Organization for Achromatopsia in Russia for the assistance in the organization of the testing of patients with achromatopsia.
About the authors:
Natella V. Sukhanova — ophthalmologist, researcher of the Laboratory of Genetic Epidemiology, Research Center for Medical Genetics, 1, Moskvorechye str., Moscow, 115522, Russian Federation; ORCID iD 0000-0003-4371-775X.
Svetlana I. Rychkova — Dr. Sc. (Med.), ophthalmologist, leading researcher of the Laboratory "Visual Systems", Institute for Information Transmission Problems of the RAS (Kharkevich Institute); 19, Bol'shoy Karetnyy lane, Moscow, 127051, Russian Federation; associate professor of the Department of Eye Diseases, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation; associate professor of the Department of Eye Diseases, Medical Biologial University of Innovations and Continuous Education of the A.I. Burnazyan Federal Medical Biophysical Center of the Federal Medical Biological Agency of Russia; 46, build. 8, Zhivopisnaya str., Moscow, 123098, Russian Federation; ORCID iD 0000-0001-6764-8950.
Vera G. Likhvantseva — Dr. Sc. (Med.), professor, professor of the Department of Ophthalmology, Academy of Postgraduate Education of the Federal Scientific and Clinical Center of the Federal Medical Biological Agency of Russian Federation; 91, Volokolamskoe road, Moscow, 125310, Russian Federation; ORCID iD 0000-0002-3175-9592.
Roman I. Sandimirov — student, Pirogov Russian National Research Medical University; 1, Ostrovityanov str., Moscow, 117437, Russian Federation.
Vitaliy V. Kadyshev — C. Sc. (Med.), geneticist, ophthalmologist, leading researcher of the Laboratory of Genetic Epidemiology, Head of the Department of Ophthalmogenetics of the Institute of Higher and Additional Vocational Education, Head of the Research Clinical Center of Genetics of Eye Diseases, Research Center for Medical Genetics; 1, Moskvorechye str., Moscow, 115522, Russian Federation.
Rena A. Zinchenko — Dr. Sc. (Med.), Corresponding Member of the RAS, Deputy Director for Scientific Clinical Work, Head of the Laboratory of Genetic Epidemiology, Head of the Department of Health Care Organization, Public Health, and Medical Genetic Monitoring of the Institute of Higher and Additional Vocational Education, Research Center for Medical Genetics; 1, Moskvorechye str., Moscow, 115522, Russian Federation.
Contact information: Natella V. Sukhanova, е-mail: natelasukhanova@gmail.com.
Financial Disclosure: no authors have a financial or property interest in any material or method mentioned.
There is no conflict of interest.
Received 12.04.2024.
Revised 19.04.2024.
Accepted 30.04.2024.
2. Abeijon Martinez S. A Review of Achromatopsia. Tr Ophtha Open Acc J. 2020;3(1):222–236. DOI: 10.32474/TOOAJ.2020.03.000154.
3. Brunetti-Pierri R., Karali M., Melillo P. et al. Clinical and molecular characterization of achromatopsia patients: a longitudinal study. Int J Mol Sci. 2021;22(4):1681. DOI: 10.3390/ijms22041681.
4. Solaki M., Baumann B., Reuter P. et al. Comprehensive variant spectrum of the CNGA3 gene in patients affected by achromatopsia. Hum Mutat. 2022;43:832–858. DOI: 10.1002/humu.24371.
5. Ishihara S. Tests for Colour Blindness. Tokyo, Japan: Kanehara Shupper Co. Ltd.; 1972.
6. Neitz M., Neitz J. A new mass screening test for color-vision deficiencies in children. Color Research Application. 2001;26(1):239–249. DOI: 10.1002/1520-6378(2001)26:1+<::aid-col51>3.0.co;2-l.
7. Barton J.S. Disorders of color and object recognition: syndromes of the ventral occipitotemporal pathway. Continuum (Minneap Minn). 2010;16(4 Behavioral Neurology):111–127. DOI: 10.1212/01.CON.0000368264.61286.9b.
8. Рычкова С.И., Лихванцева В.Г., Сандимиров Р.И. Особенности восприятия цветовых стимулов при ахроматопсии. The EYE ГЛАЗ. 2023;25(3):187–202. DOI: 10.33791/2222-4408-2023-3-187-202.Rychkova S.I., Likhvantseva V.G., Sandimirov R.I. Features of perception of color stimuli in achromatopsia. The EYE GLAZ. 2023;25(3):187–202 (in Russ.). DOI: 10.33791/2222-4408-2023-3-187-202.
9. Зольникова И.В., Рогатина Е.В. Способ диагностики ахроматопсии. Патент RU 2444977 C2. Опубл. 20.03.2012.Zolnikova I.V., Rogatina E.V. Method of achromatopsia diagnostics. Patent RU 2444977 C2 Publ. 20.03.2012 (in Russ.).
10. Schallhorn C.S., Granet D.B., Ferreyra H.A. Electronegative electroretinogram in achromatopsia. Retin Cases Brief Rep. 2018;12(2):143–148. DOI: 10.1097/ICB.0000000000000451.
11. Rosenberg T., Olsen J.V., Weisschuh N. et al. Old Mystery Solved: Achromatopsia, the Fuur Genealogy in Retrospective. Ann Case Report. 2021;6:628. DOI: 10.29011/2574-7754.100628.
12. Baraas R.C., Pedersen H.R., Hagen L.A. Single-cone imaging in inherited and acquired colour vision deficiencies. Curr Opin Behavioral Sci. 2019;30:55–59. DOI: 10.1016/j.cobeha.2019.05.006.
13. Patterson E.J., Langlo C.S., Georgiou M. et al. Comparing retinal structure in patients with achromatopsia and blue cone monochromacy using OCT. Ophthalmol Sci. 2021;1(3):100047. DOI: 10.1016/j.xops.2021.100047.
14. Kay C. Gene Therapy Updates in Achromatopsia. Intern Ophthalmol Clinics. 2021;61(4):149–155. DOI: 10.1097/IIO.0000000000000379.
15. Michalakis S., Gerhardt M., Rudolph G. et al. Achromatopsia: Genetics and Gene Therapy. Mol Diagn Ther. 2022;26(1):1–9. DOI: 10.1007/s40291-021-00565-z.
16. McKyton A., Averbukh E., Marks Ohana D. et al. Cortical visual mapping following ocular gene augmentation therapy for achromatopsia. J Neurosci. 2021;41(35):7363–7371. DOI: 10.1523/jneurosci.3222-20.2021.
17. Andersen M.K.G., Kessel L. Ametropia and Emmetropization in CNGB3 Achromatopsia. Invest Ophthalmol Vis Sci. 2021;62(2):10–19. DOI: 10.1167/iovs.62.2.10.
18. Рычкова С.И., Лихванцева В.Г., Сандимиров Р.И. Способ выявления палочкового монохроматизма у детей. Патент RU 2777211. Опубл. 25.05.2021.Rychkova S.I., Likhvantseva V.G., Sandimirov R.I. Method for detecting rod monochromatism in children. Patent RU 2777211. Publ. 25.05.2021 (in Russ.).
This work is licensed under a Creative Commons «Attribution» 4.0 License.
